Mannkind Corporation
MNKDMannkind Corporation is a biotechnology company focused on discovering, developing, and commercializing inhaled therapeutic products. It is best known for its flagship product, Afrezza, an inhalable insulin used to improve blood sugar control in people with diabetes. The company also develops other inhaled and injectable drug delivery systems aimed at providing innovative solutions for various medical conditions.
Company News
MannKind Corporation announced strong 2026 growth catalysts including FDA decisions on Afrezza label updates and pediatric indications, FUROSCIX ReadyFlow Autoinjector approval, and pipeline progress with Nintedanib DPI and Bumetanib DPI. The company closed 2025 with record Q4 revenue exceeding $100 million and completed the acquisition of scPhar...
MannKind CEO Michael Castagna sold 65,804 shares on December 17, 2025, for approximately $395,482. The sale represents a routine transaction aligned with his typical trading cadence and is not considered a warning sign. The company is performing well with strong Q3 results, FDA acceptance of a pediatric Afrezza application, and completion of the ...
Nitorum Capital fully exited its stake in Lantheus Holdings, selling 344,444 shares worth $28.2 million in Q3. The exit comes as Lantheus faces significant headwinds including a 77% year-over-year earnings decline, declining sales of its flagship prostate cancer imaging agent, CEO retirement, and margin compression despite strong revenue generati...
MannKind Corporation successfully acquired scPharmaceuticals Inc. for $5.35 per share, expanding its cardiometabolic care portfolio and expected to drive double-digit revenue growth through FUROSCIX®, an innovative therapy for heart failure and kidney disease.
MannKind Corporation announced it will acquire scPharmaceuticals for $303 million, expanding its presence in cardiometabolic and lung diseases. The deal includes an upfront cash payment of $5.35 per share and potential additional milestone payments, representing a 36% premium to scPharmaceuticals' recent trading price.
